Propelled by Strong Sequencing Business, Illumina's Revenues Grow 16 Percent in Q1

Illumina CEO Jay Flatley predicted that the number of installed next-generation sequencing platforms will eventually surpass that of capillary electrophoresis sequencers, estimated at about 15,000, as sequencing costs continue to decline and as applications expand.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.